pre-IPO PHARMA
COMPANIES
VC
JOBS
NEWS
CONTACT
Close ×
COMPANIES
VC
JOBS
NEWS
CONTACT
aztherapies PRESS RELEASE ARCHIVE
Nov 18, 2020
AZTherapies Completes COGNITE Phase 3 Alzheimer’s Clinical Trial; Top-Line Data Readout Expected in First Quarter of 2021
Aug 11, 2020
AZTherapies Announces the Appointment of Drs. Robert Malenka, Adam Boxer, Vijay Kuchroo and Megan Levings, to Scientific Advisory Board
Jul 22, 2020
AZTherapies Strengthens Board of Directors and Business Advisory Board with New Appointments
Nov 6, 2019
AZTherapies Announces Appointment of Ernest D. Penachio as Vice President of Manufacturing Operations and CMC
Oct 24, 2019
AZTherapies Strengthens Neuroinflammation-Targeted Pipeline Through Acquisition of Smith Therapeutics
Aug 7, 2019
AZTherapies Announces Appointment of Pharma Industry Veteran George D. Behrakis to its Board of Directors
Jul 10, 2019
AZTherapies Strengthens Management Team, Adding Industry Veteran Jay Mohr as Chief Operating and Business Officer, Head of Commercial Development
Jan 31, 2018
A new publication confirms AZTherapies's innovative drug combination approach to address the neuroinflammation response via neuro-immunology and amyloid beta accumulation associated with neurodegeneration and Alzheimer's disease. Deutschland - Deutsch Nederland - Nederlands France - Français Brazil - Português Latin America - español USA - English
Oct 31, 2017
AZTherapies, Inc. appoints Karen Reeves, MD as President and Chief Medical Officer Deutschland - Deutsch Nederland - Nederlands Brazil - Português USA - English Latin America - español France - Français
Sep 15, 2015
AZTherapies Commences Phase III Pivotal Trial - for ALZT-OP1 in Early Alzheimer's Disease
May 23, 2014
AZTherapies cleared to start enrolling under their IND for a Phase III clinical efficacy study for ALZT-OP1 in early Alzheimer's disease
